TY - JOUR
T1 - Onset of efficacy of tolterodine extended release in patients with overactive bladder
AU - Sussman, David O.
AU - Kraus, Stephen R.
AU - Carlsson, Martin
AU - Guan, Zhonghong
N1 - Funding Information:
This study was funded by Pfizer Inc. Martin Carlsson and Zhonghong Guan are employees of Pfizer Inc. The authors acknowledge the editorial assistance of Melinda Ramsey, PhD from Complete Healthcare Communications, Inc. in the preparation of this manuscript. Editorial support was provided by Pfizer Inc.
PY - 2007/4
Y1 - 2007/4
N2 - Objective: To assess the onset of efficacy of tolterodine extended release (ER) in patients with overactive bladder (OAB). Research design and methods: A post hoc analysis was conducted using 3-day bladder diary data from a 12-week, multicenter, prospective, open-label study of tolterodine ER (4 mg qd) in patients (aged ≥ 18 years) with urinary frequency (≥ 8 micturitions/24 h) and urgency (strong and sudden desire to urinate) with or without urgency urinary incontinence (UUI). Main outcome measures: Changes in micturition frequency, urgency, and UUI episodes/24 h were evaluated for treatment Days 5, 6, and 7. The percentages of patients who achieved normal micturition frequency (< 8/day) and 50%, 70%, 90%, and 100% reductions in urgency and UUI episodes (i.e., responders) were determined at Days 5, 6, and 7. Week 12 data are presented as a referent for the magnitude of treatment efficacy during Week 1. Results: This analysis included 698 patients. On Day 5, there were significant reductions in all three diary variables (all p < 0.0001), and improvements continued on Days 6 and 7. More than half of the patients reported ≥ 50% reductions in urgency or UUI episodes on Day 5. Responder rates for all three symptoms increased through Week 12. Conclusions: Patients with OAB experienced significant reductions in OAB symptoms as early as Day 5 of treatment with tolterodine ER. These data extend the findings of a previous analysis, in which all 3 days of the bladder diary were pooled, that demonstrated improvements in micturition frequency, urgency episodes, and UUI episodes in patients with OAB after 1 week of treatment with tolterodine ER. Limitations are that efficacy was not assessed before Day 5, this was a post hoc analysis, and the study was not placebo-controlled.
AB - Objective: To assess the onset of efficacy of tolterodine extended release (ER) in patients with overactive bladder (OAB). Research design and methods: A post hoc analysis was conducted using 3-day bladder diary data from a 12-week, multicenter, prospective, open-label study of tolterodine ER (4 mg qd) in patients (aged ≥ 18 years) with urinary frequency (≥ 8 micturitions/24 h) and urgency (strong and sudden desire to urinate) with or without urgency urinary incontinence (UUI). Main outcome measures: Changes in micturition frequency, urgency, and UUI episodes/24 h were evaluated for treatment Days 5, 6, and 7. The percentages of patients who achieved normal micturition frequency (< 8/day) and 50%, 70%, 90%, and 100% reductions in urgency and UUI episodes (i.e., responders) were determined at Days 5, 6, and 7. Week 12 data are presented as a referent for the magnitude of treatment efficacy during Week 1. Results: This analysis included 698 patients. On Day 5, there were significant reductions in all three diary variables (all p < 0.0001), and improvements continued on Days 6 and 7. More than half of the patients reported ≥ 50% reductions in urgency or UUI episodes on Day 5. Responder rates for all three symptoms increased through Week 12. Conclusions: Patients with OAB experienced significant reductions in OAB symptoms as early as Day 5 of treatment with tolterodine ER. These data extend the findings of a previous analysis, in which all 3 days of the bladder diary were pooled, that demonstrated improvements in micturition frequency, urgency episodes, and UUI episodes in patients with OAB after 1 week of treatment with tolterodine ER. Limitations are that efficacy was not assessed before Day 5, this was a post hoc analysis, and the study was not placebo-controlled.
KW - Bladder
KW - Tolterodine
KW - Urinary incontinence
KW - Urinary tract
UR - http://www.scopus.com/inward/record.url?scp=34247364005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247364005&partnerID=8YFLogxK
U2 - 10.1185/030079907X178801
DO - 10.1185/030079907X178801
M3 - Article
C2 - 17407634
AN - SCOPUS:34247364005
SN - 0300-7995
VL - 23
SP - 777
EP - 781
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 4
ER -